-1760473974116.webp&w=3840&q=75)
Emerging Therapies in the Treatment of Parkinson's Disease
Course Overview
Healthcare providers must stay informed about emerging and reformulated therapies to assess benefits and risks, educate patients, set expectations, and adopt effective treatments that improve QoL. After this course, providers will be able to evaluate therapies that are newly available or in development.
Course Objectives
Evaluate the evidence, efficacy, and safety profiles of pipeline therapeutics for treating Parkinson’s Disease
Compare the potential clinical benefits and limitations to current standard treatments for Parkinson's disease
Assess the implications of emerging therapies on clinical decision-making and patient management strategies
Target Audience
This course is for movement disorder specialists, neurologists, advanced practice providers, and other healthcare professionals involved in the care of patients with a movement or related disorder.
Credit Information
Credit Type
* AMA PRA Category 1™
Number of Credits
1
* AMA PRA Category 1 ™ credits are used by physicians and other groups like PAs and certain nurses. Category 1 credits are accepted by the ARDMS, CCI, ACCME, and Sonography Canada.
Faculty
Zoltan Mari, MD, faculty for this educational event is on the speakers bureau for ACADIA Pharmaceuticals and Supernus; Consultant for ACADIA Pharmaceuticals, AbbVie Inc., and Amneal Pharmaceuticals.
This activity was supported by an independent educational grant from Boston Scientific.
Disclosure
None of the planners, or moderators for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing products used by or on patients. All of the relevant financial relationships listed for these individuals have been mitigated. Remaining persons in control of content have no relevant financial relationships.
Estimated Time for Completion
1 hour
Date of Release
October 15th, 2025
Date of Most Recent Review
October 15th, 2025
Expiration Date
October 15th, 2028